Connect with us

Press Release

UniArt’s impossible art formula gallery bring bottom-up NFT appreciation with vote mining on 30th Sep

Published

4 years ago

on

Preamble

Recently, “Loot” has been spreading virally throughout the crypto community. Industry key opinion leaders (KOLs), founders of quality projects, and investment institutions all pay close attention to the emerging “bottom-up” concept, and more community members are excited about it.

Despite the term bottom-up only recently coming into the limelight, in essence, the philosophy may be at the root of the entire crypto economy. Bitcoin, for example, breaks the rules of centralized government-issued fiat currency by enabling anyone that follows its PoW consensus algorithm to produce a new currency. On the other hand, Ether allows developers to build arbitrary dApps on top of it without permission, and its prosperity hinges on the frequency of this.

These two patriarchs of the crypto economy have opened up a bottom-up path outside the centralized internet. The bottom here can be anyone. The top is no longer governments or corporations but now code, algorithms, data, and consensus mechanisms. Loot is the first bottom-up non-fungible token (NFT), possessing similar intrinsic characteristics at the root of its explosion.

The most widespread application of NFT is currently in the art sector. Crypto community practitioners are working to bring NFT into the traditional art marketplace. To accomplish this, NFT must have general acceptance and market consensus, not just within a niche group of artists and appreciators. Take the most common financial application of collateralized lending, for example; a starving artist, globally unknown pledges his minted NFT to you, the potential lender. They claim it is worth US$10,000 and want to borrow against this collateralized value. Naturally, you are hesitant, unsure of its market value, and even if a current buyer is willing to purchase it at that price, you are still uncertain about its future value. In short, there is not enough market consensus for that NFT. However, let’s use CryptoPunk or BAYC as collateral in this example. Results would be the opposite because each of these digital assets already has widespread market consensus, having been classified as antiques in the NFT community. Therefore, the fair market valuation of NFT is critical to achieving market consensus in the financial sector. Exploring a suitable value solution for NFT is beneficial in a financial application, which opens up various other possibilities for NFT, leading to the further development of the whole crypto community.

UniArts aims to uncover NFT fair market valuation through its customized bottom-up Nominated Proof-of-Stake (NPoS) economic model, aspiring decentralized incubation of creators and their works. In this paper, the core concept of UniArts will be comprehensively explained using this bottom-up concept as the source idea.

Bottom-up NFT Fair Market Valuation

The term bottom-up can be understood differently in different contexts; building on top of a foundation is not a required characteristic. In the context of UniArts, bottom (in a non-pejorative sense) can be understood as what people define together and top as the fair value of NFT. This bottom-up approach is contrasted with more traditional top-down valuation, which was determined mainly by centralized auction houses or prominent collectors. Less renowned artists rarely gained any attention, and in the rare chance they did, their work would often be considered nearly worthless. Such an approach does nothing to showcase potentially exceptional pieces for the mere reason they are unknown, and they remain misunderstood by the public.

In the UniArts network, $UART holders are deemed “nominators,” pledging their tokens as “votes” for an NFT they admire. The more votes an NFT receives, the more people approve of it, and the higher the consensus level. When people are required to invest in their decisions, they become much more selective. Since there is value in $UART, the votes that an NFT receives indicate its fair market value. In the early stages of UniArts’ development, the small user base may not be sufficient to tie the word fair to an NFTs value, but as the network expands, it will become more and more convincing. This process can be referred to as the “flywheel effect.”

Appreciate to Earn

“Appreciate To Earn” is a new concept and a subset of “Play To Earn,” in that merely appreciating an NFT is akin to the process of playing. Axie Infinity, a chain game that has been popular in the crypto community for a while now, relied on this “Play To Earn” concept as the fuel to expand its user base. From this vetted example, we know that it is a viable business model.

UniArt’s Nominators pledge $UART and select an NFT they appreciate to earn more $UART, including a base pledge bonus and a block bonus for top-ranked NFTs. In this process, the word appreciate corresponds to the nominator, and the word earn corresponds to the earned $UART. In Axie Infinity, players buy a pet “Axie” as an entry ticket to the game and earn revenue in-game from this Axie. In UniArts, $UART is the entry ticket into the network.

Play to Earn can be viewed as a modern concept to attract new users. Traditional game companies pay third-party advertising companies to attract new users, but these users do not receive any income. Blockchain games use tokens to incentivize new users, which is a disguised way of attracting traffic; an alternative form of advertising, where the fees paid to advertising companies are instead attributed to the user. If this alternative form of advertising is integrated into a chain game’s economic model, one can only expect explosive organic user growth. Similarly, the Appreciate to Earn concept will cause natural growth of UniArt’s user base, eventually to the point where fair valuation is achieved.  

Multi-Chain NFT Gallery “Impossible Art Formula”

UniArts is native to Polkadot, and one of its strategic plans is to spread the NFT gallery to more popular blockchains, the first stop being Polygon. Mechanically, the gallery will be similar to the NPoS economic model but not identical.

  • Six NFTs will be presented in each issuance, and users can pledge $UART or $WETH to vote on their favorite NFT.
  • There are a total of 3 revenue pools, including a casting pool, a general pool, and a bonus pool. The bonus pool added to the gallery is unique in comparison to the NPoS model mentioned above. The casting pool is a pool in which $UART is minted into an NFT based on the percentage of votes received by the NFT. The general pool allocates rewards based on the proportion of user votes to the total number of votes in the corresponding NFT.
  • At the end of each voting period, NFT owners have the option to participate in the next three-day auction. The bonus pool is allocated to the corresponding NFT according to the ratio of the price sold in the auction to the sum of all prices traded in the auction for that period. This pool is then allocated to users that voted in the general pool, as mentioned in (2).
  • Specific details can be found in the following chart:

UARTs tokens are capped at 200 million, with 10% held by the team and released after 3 years, 12% by early stage investors, 10% by the treasury, and the rest by NFT vote mining, “Appreciate To Earn”.

“Impossible Art Formula” demonstrates the lack of a perfect solution in art valuation as everyone has their unique preferences. Let’s solve this by using $UART to appoint the “Hamlet” we fancy.

Concluding Remarks

UniArts has customized the NPoS economic model for NFT with an Appreciate To Earn mechanism based on the bottom-up source concept, which helps NFT discover its fair value. This value discovery fills an essential gap in applying NFT to traditional art and financial systems, paving a new path in crypto circles.

The impossible art formula is accessible now and will be online on 30th Sep.

About Author

Alex Jacob

Alex Jacob is a literature author. He was born in Chicago. Alex passion is writing news articles. He writes number of articles and published it.

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

Published

28 minutes ago

on

January 30, 2026

By

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.

Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.

The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.

This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health.

Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.

About Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. 

More About Ruxolitinib Phosphate Cream

Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).

Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.

 

About CMS

 

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group.

 

Reference:

  1. The U.S. FDA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream

  1. The EMA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar

  1. The clinical studies information can be found on the Opzelura® official website, as follows:

https://www.opzelura.com/opzelura-prescribing-information

  1. China Insights Consultancy’s industrial report

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Gabriel Malkin Florida Completes 120-Mile Camino Walk with Focus, Patience, and Preparation

Published

5 hours ago

on

January 30, 2026

By

Florida, US, 30th January 2026, ZEX PR WIRE, Most students don’t spend the start of summer walking across northern Spain. Gabriel Malkin did. In June 2025, the Florida high school graduate completed a 120-mile stretch of the Camino de Santiago, one of the world’s oldest pilgrimage routes. It wasn’t a last-minute idea. It was a goal he had planned for, trained for, and quietly worked toward for months.

This wasn’t about adventure or social media. For Gabriel, it was about setting a physical goal and showing up for it every day.

“I didn’t want to wing it,” he said. “It was important to take it seriously.”

Gabriel’s prep started long before his flight to Europe. He built up mileage slowly, starting with short daily walks in South Florida. As the months went on, he added distance, tested gear, and paid attention to recovery. Blisters, sore muscles, and weather were all part of the process. So was building patience.

“The Camino isn’t just hard because it’s long,” Gabriel said. “It’s hard because you have to get up and do it again every day. Even when you’re tired. Even when nothing hurts and you feel fine—you still have to walk.”

The daily rhythm became its own challenge. Mornings often started before sunrise, with quiet stretches of trail through farmland, hills, and towns. Gabriel carried a small pack with essentials. Water, snacks, extra socks. No Wi-Fi. No schedule beyond the day’s distance. Just a clear goal and a few hours of steady effort.

That focus and consistency mirrors how Gabriel approaches most things. Whether he’s in class, on the tennis court, or working on saxophone tone, he tends to favor structure and repetition over shortcuts. It’s not about perfection. It’s about showing up, improving slowly, and staying with it.

“I’ve never been the fastest or the strongest at anything,” he said. “But I like knowing I’m getting better, even if it’s slow.”

Gabriel grew up in South Florida and attended Virginia Shuman Young Elementary, Pine Crest in Fort Lauderdale, and NSU University School in Davie. He played tennis, baseball, and football through different stages of school. He also spent time hiking local trails and practicing saxophone, two interests he says helped him train for the Camino more than people might expect.

“Hiking helped with endurance, obviously,” he said. “But playing music teaches you a lot about repetition and listening to your body. You learn when to push and when to pause.”

For Gabriel, the Camino wasn’t a performance or a competition. It was a quiet personal test. He kept notes during the walk, not for a blog, but to track how each day felt. When he crossed the finish line in Santiago, there was no big moment. Just a quiet sense of completion.

Now back home, Gabriel hasn’t stopped walking. He’s back to local trails, early mornings, and training logs. He’s also thinking about what comes next—college, travel, more endurance goals—but isn’t rushing anything.

“There’s no rush,” he said. “The Camino reminded me that showing up every day matters more than trying to get somewhere fast.”

Gabriel Malkin Florida continues to build habits rooted in preparation, consistency, and follow-through. Whether through athletics, academics, or music, his focus remains steady: stay curious, stay active, and finish what you start.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Jon DiPietra Debunks 5 Real Estate Myths That Mislead New Yorkers

Published

5 hours ago

on

January 30, 2026

By

  • Jon DiPietra, a New York–based real estate valuation executive, explains why common beliefs about space and value often miss the mark.

New York, US, 30th January 2026, ZEX PR WIRE, New York City is full of opinions about real estate. Many of them are repeated so often they start to feel true. But according to Jon DiPietra, decades of hands-on valuation work tell a different story.

“You learn things you cannot see in a report,” DiPietra says. “That’s where most of these myths fall apart.”

Below are five common myths that mislead everyday people across dense urban markets, why they persist, and what actually matters instead.

Myth 1: Bigger Space Always Means Better Value

Why people believe it:
Square footage is easy to compare. Listings highlight size first, so people assume more space equals more value.

The reality:
In dense cities, efficiency matters more than size. Studies show poorly used space can reduce productivity by up to 30 percent, even when square footage increases.

As DiPietra puts it, “The goal is not to produce the highest number. The goal is to produce something that makes sense in the real world.”

Try this today:
Identify one underused area in your home or office and repurpose it for a single clear function.

Myth 2: National Data Tells You Everything You Need to Know

Why people believe it:
Online tools and national reports feel authoritative and precise.

The reality:
Real estate is hyper-local. In New York, conditions can change block by block. National averages often lag reality by months.

“Real estate is ultimately driven by people, not formulas,” DiPietra says.

Try this today:
Walk your block at different times of day. Notice noise, foot traffic, and how spaces are actually used.

Myth 3: If a Space Worked Before, It Should Still Work Now

Why people believe it:
People resist change and assume layouts age well.

The reality:
How we live and work has shifted fast. Surveys show nearly 60 percent of people say their space no longer supports how they work today.

“Clear thinking matters more than being busy,” DiPietra notes.

Try this today:
Ask one simple question: What do I actually do here every day? Adjust one thing to support that reality.

Myth 4: More Information Leads to Better Decisions

Why people believe it:
Data feels safe. More feels smarter.

The reality:
Too much information can slow decisions and increase stress. Research links information overload to poorer judgment.

DiPietra says, “More data does not always lead to better decisions.”

Try this today:
Limit yourself to three criteria when evaluating a space or decision. Ignore the rest.

Myth 5: You Need a Major Renovation to Fix a Space

Why people believe it:
Media and social platforms spotlight dramatic transformations.

The reality:
Small changes often have outsized impact. Lighting, noise reduction, and decluttering consistently rank among the highest-return improvements.

“Sometimes the simplest changes create the most lasting value,” DiPietra says.

Try this today:
Improve lighting where you spend the most time. It is one of the fastest ways to change how a space feels.

If You Only Remember One Thing

Spaces influence behavior more than most people realize. When a space creates friction, it is often a design problem, not a personal one.

Understanding how space actually functions is more valuable than following assumptions or averages.

Call to Action
Share this myth list with someone who lives or works in a dense city. Pick one practical tip above and try it today. Small changes, applied intentionally, add up.

About Jon DiPietra
Jon DiPietra is a New York–based commercial real estate valuation executive and cofounder of H&T Appraisal, the valuation group of Horvath & Tremblay. With more than 20 years of experience, he has worked across residential, commercial, mixed-use, and special-use properties, focusing on how real people actually use space.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us